Sensors that can detect volatile organic compounds present in the breath of lung-cancer patients (and for certain other ailments, such as liver failure), using an array of small, inexpensive gold nanoparticles, have been developed by Israel Institute of Technology researchers.

Clinical trials are expected within two or three years.